Issue link: https://viewer.e-digitaledition.com/i/1481285
A BOUT 10% OF children in the United States have been diagnosed with asthma. According to studies, a large majority of these chi ldren a lso have a llerg ies. Researchers working on the clinical trial Preventing Asthma in High Risk Kids (PARK) seek to determine whether early intervention with Xolair in young children with a llergies ca n a lter the processes that eventually lead to the development of asthma. "PARK's goal is to determine if early interruption of immunoglobulin E (aller- gic) mediated pathways in children ages 2 to 3 can prevent or modify the course of asthma in high-risk children," says Wanda Phipatanakul, MD, MS, Director of the Asthma Clinical Research Center at Boston Children's Hospital and lead researcher of the PARK study. "We hope that blocking these processes early in life, when a high- risk child is beginning to develop disease processes but prior to the full development of established disease, could have lasting benefit and prevent asthma and/or reduce the severe progression of asthma later on in life." EARLY PREVENTION Studies show as many as 80% of children who have allergies and wheezing episodes between the ages of 2 to 3 will develop asthma during childhood. W hile treat- ments can reduce symptoms, nothing has been proven to prevent the progression to asthma. Xola ir works by blocking immuno- globulin E (IgE), antibodies released in response to a llergens such as pollen and mold spores. IgE antibodies attach to mast cells, which release histamine and trigger a sthma a nd a l lerg ic responses. Ma st cells a lso curb the creation of Treg cells, regulatory T cells that work to control the immune response. Researchers hope that by blocking the immune events caused by IgE antibodies, the processes that lead to asthma can be thwarted. While Xolair is FDA-approved for use in people ages 6 a nd older with moderate to severe asthma, it has not yet been tested in younger children who are only developing a llergies. A COMPREHENSIVE STUDY The PARK study is a randomized, dou- ble-blind trial that will study 250 children ages 2 and 3 at multiple research facilities. " We are focused on children at high risk who are already beginning to develop symptoms," Dr. Phipatanakul says. "We have targeted high-risk children as those who are allergic to allergens and starting to wheeze who also have a family history of asthma or allergies." Children in the trial will be given either Xolair or a placebo monthly for a two- year period. Researchers will continue to follow them for two more years after the treatment period to observe if and how many children from each group progress to asthma. n To learn more about the PARK trial, visit parkstudy.org. Can the Development of Pediatric Asthma Be Prevented? BY ELESA SWIRGSDIN A NE W STUDY LED BY RESE ARCHERS AT BOSTON CHILDREN'S HOSPITAL AIMS TO DE TERMINE WHE THER MONOCLONAL ANTIBODY XOL AIR (OMALIZUMAB) CAN STOP OR LESSEN THE PROGRESSION OF A STHMA IN HIGH-RISK CHILDREN. Up to 80% of children with allergies and wheezing at 2–3 years old will progress to pediatric asthma. 1 4

